International Journal of Technology Assessment in Health Care

Papers
(The TQCC of International Journal of Technology Assessment in Health Care is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
PP114 The Influence Of Implicit Factors On The Health Technology Assessment Deliberative Process: A Survey In Five European Countries189
PP150 The Role Of Expert Consensus In UK Guidance: Patient Selection For Hydrogel Spacer Use During Prostate Cancer Radiotherapy49
PP53 Applying The VALIDATE Approach To Frame The Assessment Of Integrated Care Management In Aortic Valve Stenosis35
PP97 Recommendations For Generating South African Health-Related Quality Of Life Data For Cost-Utility Analyses30
PD35 Mortality And Risk Factors Associated With Dialysis Patients With COVID-19 In A Brazilian Supplementary Health Service24
PD09 Comparing Long-term Costs Associated With Intraocular Lens Selection And Nd:YAG Laser Capsulotomy In The UK: A Cost-Consequence Analysis22
OP82 Positron Emission Tomography Combined With Computed Tomography Using 18F-Sodium Fluoride21
PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands21
OP92 Impact Of Real-World Evidence On Health Technology Assessment And National Guidance For Interventional Procedures: A UK Perspective21
OP42 Increasing Access To Real-World Data To Move From Health Technology Assessment To Health Technology Management21
PP23 Lost In Translation? The Differences In The Use Of Real-World Evidence Across Key Markets21
PP97 How Health Technology Agencies Estimate Target Population Size For Medical Devices: The Example Of Spinal Cord Stimulation20
OP128 Uncertainties In The Cost-Effectiveness Analysis Of Onasemnogene Abeparvovec For Spinal Muscular Atrophy Type 118
PP11 Patient Involvement In Drug Evaluations To Inform Funding Decisions: A Singapore Case Study18
PP105 Efficacy, Effectiveness And Safety Of Letermovir For Prophylaxis Of Cytomegalovirus Infection And Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation17
PP79 Publication Trends Of Network Meta-analyses In Europe And Asia: A Focus On Cardiovascular Disease15
PP38 Designing A Training And Capacity Building Pathway In Patient Involvement15
OP19 Exploring The Environment/Capacity Of South African Citizen Actors To Contribute To Health Technology Assessment Processes, Policy Development And Institutionalization15
Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury13
OP60 Methodological Guidance And Doctrine Of The French National Authority For Health For Economic Evaluation13
PD137 Reviewing The Health Technology Assessment And Regulatory Policy Landscape On Acceptability Standards For Real-World Evidence - Initial Findings13
PD149 Comparison Of The Draft European Union Health Technology Assessment Template With Germany’s AMNOG Template12
PD208 Optimal Scheme For Molecular Diagnosis Of BRCA1/2 Gene Mutations In Patients With Breast Cancer In Poland - Cost-Utility Analysis12
OP76 Cost-Effectiveness Of Offering Human Papillomavirus Self-Sampling To Non-Attendees Of Organized Primary Cervical Cancer Screening In Germany12
PD129 Extension Of An Influenza Vaccination Program To Include Those Aged 50 To 64 Years: A Rapid Health Technology Assessment Approach11
PD10 Cost Effectiveness Analysis Of Etranacogene Dezaparvovec Versus Factor IX Prophylaxis In Adult Men With Hemophilia B From Brazil11
PP07 One Bad Apple Can Spoil The Barrel: Are We Effectively Evaluating Software As A Medical Device?11
OD12 Large Language Models As Powerful Tools In Health Technology Assessment11
PP56 National Immunization Technical Advisory Groups Are Essential For Successful Implementation Of The European Health Technology Assessment Regulation11
Reframing Early Health Technology Assessment Through a Lifecycle Lens: Commentary on “Defining Early Health Technology Assessment: Building Consensus Using Delphi Technique”10
PP92 Enhancing Patient Engagement In Health Technology Assessment: Identification Of Barriers, Facilitators, And Proposals For Improvement10
OP25 Rapid Molecular Tests For Detecting Multidrug-Resistant Microorganisms: An Overview Of Systematic Reviews Within A Living Evidence Project10
An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report9
Development and implementation of a value framework for rapid health technology assessment reports: enhancing evidence-informed decision making in resource-constrained settings9
Methods and criteria for the assessment of orphan drugs: a scoping review9
Health technology assessment in traditional and complementary medicine: a scoping review of international activity and examples of acupuncture9
Nonsurgical periodontal treatment in type II diabetics in a middle-income country: a cost-effectiveness analysis9
Designing collaborations involving health technology assessment: discussions and recommendations from the 2024 health technology assessment international global policy forum9
A model-based study to estimate the health and economic impact of health technology assessment in Thailand9
Mapping frameworks for synthesizing qualitative evidence in health technology assessment9
PP86 Cost Effectiveness Of Maternal Respiratory Syncytial Virus (RSV) Prefusion F (RSVpreF) With Complementary Nirsevimab Versus Nirsevimab Alone For Preventing RSV Among Infants In Chile8
PP36 Comparing Artificial-Intelligence-Generated And Expert-Driven Chemotherapy Recommendations For Node-Positive Breast Cancer8
OP66 Assessment Of Patient And Public Involvement Reporting In Health Technology Assessment Documents In Brazil (2023 To 2024)8
Economic evaluation and costs of remote patient monitoring for cardiovascular disease in the United States: a systematic review8
PP149 A Multidimensional And Multistakeholder Approach: Assessing Ethical, Legal, Organizational, Social or Patient-centered (ELSI+) for Telemedicine In Neurological Diseases7
PP118 Cyclic Mental Health Technology Assessment with Priority Setting And Involving Stakeholders - A Case Report From The Netherlands7
Eliciting uncertainty for complex parameters in model-based economic evaluations: quantifying a temporal change in the treatment effect7
PP09 Use Of Real-World Evidence For Managing Health Technologies Throughout The Life Cycle Of Transcatheter Aortic Valve Interventions7
PD33 Exploring The Influence Of Patient Preference Information In Health Technology Assessment: Insights From Mock Deliberations With Agencies7
A first exploration of the economic consequences of an autonomous surgical robot for lateral skull base surgery: an early health technology assessment7
The role of health economics within health technology assessment: past, present, and future – an Austrian perspective7
A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies7
OP90 Optimizing Health Technology Assessment And Appraisal For Orphan Drug Reimbursement: Experiences And Tools For Improvement7
Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers’ Information Sources7
PP09 Fecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: A Systematic Review And Multiple-Threshold Meta-Analysis6
OP176 Integrating Real-world Compliance In The Assessment Of Left Atrial Appendage Closure Versus Anticoagulation Therapy In Non-valvular Atrial Fibrillation6
OP27 Impact Of Generic Entry Of Pharmaceuticals On Drug Prices In Australia6
OP167 An Analysis Of Medication Exclusion Reports In The Health Technology Assessment Process For The Brazilian Unified Health System6
PP146 Seeing Eye-To-Eye on Real-World Evidence: Are Guidance from Japan and China Consistent with Recommendations from REALISE in Asia?6
OP80 Generating Patient Preference Evidence For Health Technology Assessment: A Sustainable Roadmap6
OD11 Application Of Natural Language Processing To Predict Final Recommendation Of Brazilian Health Technology Assessment Reports6
Decision making for early surgical technology adoption into Canada’s healthcare system: a scoping review of the decision-making criteria, challenges, and opportunities6
OP46 The Decision Uncertainty Toolkit: Risk Measures And Visual Outputs To Support Health Technology Decision-making During Public Health Crises6
A value framework for lymphoma therapies based on MACBETH method6
PD71 Survival Outcomes And Adherence To Defined Daily Doses Of Imiglucerase: A 16-Year Brazilian Cohort Study In Gaucher Disease6
Integrating organizational impacts into health technology assessment (HTA): an analysis of the content and use of existing evaluation frameworks6
Economic evaluation of genomic/genetic tests: a review and future directions6
OP126 Clinical And Economic Evaluation Of The Effectiveness Of Cerebrolysin® In Neurological Patients With Post-Stroke Complications In Kazakhstan6
The HTAi early HTA definition: a welcome milestone, and what must follow6
PD203 Comparison Of Health Technology Assessment Methodologies Across Australia, Canada, New Zealand And The United Kingdom: Implications For Future Collaboration6
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs5
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology5
A review of HTA guidelines on societal and novel value elements5
PP13 Access Barriers After The Incorporation Of Technologies Into The Unified Health System In Brazil5
Acknowledgements5
Perception of non-layperson advisory committee members on the application of a discrete choice experiment instrument to patients and advisory committee members: a qualitative study5
The potential of the hospital-based Health Technology Assessment: Results of a world-wide survey5
Developing and piloting a context-specified ethics framework for health technology assessment: the South African Values and Ethics for Universal Health Coverage approach5
PD75 Evolution Of Health Technology Submissions In The Unified Health System: Analysis Of National Committee For Health Technology Incorporation (CONITEC) Evaluations (2012 to 2024)5
Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling5
Toward including environmental sustainability in Health Technology Assessment5
Health technology assessment and healthcare environmental sustainability: Prioritizing effort and maximizing impact5
PP54 Next Generation Sequencing Gene Panel For Medical Lung Cancer Medical Care5
OP17 Updated Cost-Effectiveness Threshold Estimates For 174 Countries Based On Projected Growth In Life Expectancy, Health Expenditure, And Gross Domestic Product5
OP136 A Comparison Of Health Technology Assessment Recommendations In Australia, Canada, And England: Is There Opportunity For Further Alignment?4
OP62 Trends In Uncertainties And Outcomes Following An Assessment Of Cancer Topic Suitability For The Cancer Drugs Fund4
PD32 Opportunities And Challenges: Health Technology Assessment Body Perspectives On The Integration Of Artificial Intelligence In Evidence Synthesis4
OP105 Gaps, Challenges And Priorities For Neurodegenerative Disease Research And Health Technology Assessment4
Acceptability of self-administered antigen test for COVID-19 in the Philippines4
PD05 Novel Non-Thermal Ablation Technology For The Treatment Of Atrial Fibrillation4
Building capacity in horizon scanning, early awareness, and disinvestment: a framework for education and training4
Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines4
OP163 Applying A Local Economic Evaluation Framework To Make Evaluations More Relevant For Local Decision Makers4
OP63 Life Cycle Health Technology Assessment: Brazil’s Experience With CONITEC4
Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders’ perspectives4
OP44 Does The Health Economic Modelling Structure Matter? An External Validation Of Three Approaches Commonly Used In Obesity Modelling4
Patient perspectives on continuous glucose monitoring system (CGMS) for diabetes in Malaysia: a vital voice in health technology assessment (HTA) informing decision-making4
Analysis of consumer comments into PBAC decision-making (2014–9)4
PD177 The Effect Of COVID-19 On Cancer Screening In Brazil, Canada, And The USA: A Cross-National Study4
PD33 Development And Validation Of A Machine Learning-Based Prediction Model For COVID-19 Diagnosis Using Patients’ Metabolomic Profile Data4
OP51 Use Of Real-World Data In Cost-effectiveness Analysis Of Sequential Biologic Treatment For Rheumatoid Arthritis4
OP08 A Comprehensive Collaborative Framework To Enhance Orphan Drug Accessibility For Rare Diseases: Insights From Türkiye4
OP65 An Overview Of Participatory Approaches, Stakeholders, Methods, Topics and Challenges In Medical Device Development: A Scoping Review4
PP70 Mapping Of Health Technology Assessment In China: A Comparative Study Between 2016 And 20214
PP111 Reimbursement And Payment Models: A Survey Of Stakeholders’ Current Experiences And Future Outlook Within The Dutch Policy Setting4
PD22 Exploratory Analysis of a Brazilian Real-World Open Database Applied to Prostate Cancer4
A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK4
Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment3
PD42 Should Antibiotics Be Used To Treat Recurrent Otitis Media In Children? Updating A Recommendation3
PD124 Genicular Artery Embolization For The Treatment Of Knee Osteoarthritis: A Systematic Review And Meta-analysis3
PP34 Impact Of The COVID-19 Pandemic On Depression Incidence And Healthcare Service Use Among Patients With Depression3
OD14 Harmonization Of HTA For Digital Health Technologies: The EU-Funded European Digital Health Technology Assessment Project3
PD186 Treat-To-Target In Gout: Are Private General Practitioners In Malaysia Riding The Evidence-Based Wave?3
PP37 Guidance On Using Hospital-Based Real-World Evidence In Health Technology Assessments For Oncology3
Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTA3
OD39 Evaluation Of Sustainability And Environmental Impact Measures In Health Technology Assessment Of Medical Technologies In Europe: Starting An Important Journey3
PP57 Outcomes Model For Assessing Strategies Improving In Vitro Fertilization Birth Rates3
PD231 A New Way Of Identifying And Selecting Health Technology Assessment Topics: Using Social Media And Citizen Involvement3
PD199 Global Collaboration Post-Brexit: Do Project Orbis And The Access Consortium Improve Access In The UK Compared With Europe?3
Development and validation of a type 2 diabetes model to estimate the cost-effectiveness of diabetes interventions across the care continuum3
OP50 BRISA: Regional Database Of Health Technology Assessment Reports Of The Americas3
OP70 Implementation Of An Online Consultation Hub To Facilitate Consumer Engagement In Health Technology Assessment Processes3
OP01 Impact Of Cost Heterogeneity On Assessing The Value Of Gene Therapies3
PP55 Health Technology Assessment Scoping Definition For Health Regulation3
PD133 Exploring Real-World Data Based Financing Models For Lung Cancer Immunotherapy In The Czech Republic3
OD30 Clinician-Driven Health Technology Assessment: National Cancer Medicines Review For Off-Label Uses And On-Label Off-Patent Uses In NHSScotland2
PP45 Budget Impact Analysis Of Including Bictegravir/Emtricitabine/Tenofovir Alafenamide In First-Line Antiretroviral Therapy For HIV/AIDS In Chile’s Explicit Health Guarantees2
Implementing a sandbox approach in health technology assessment: benefits and recommendations2
OP31 Monitoring Of The Budget Impact Determinants Of Incorporated Technologies For Rare Diseases In The Brazilian Health System2
OP79 Incorporating Environmental Impacts Into Health Technology Assessment: An Examination Of Potential Approaches And Challenges2
Response to heterogeneity of tests and platforms in economic evaluations: synthetic model adoption; derivatives of transferable practice2
PD50 Does The New Healthcare Reform Improve Job Satisfaction Among Village Clinic Doctors In China? A Meta-Analysis2
PD61 Thromboprophylaxis After Major Orthopedic Surgeries: Health Technology Assessment To Promote Access To Oral Anticoagulants2
PP41 COVID-19 Modeling To Support Decision Making In Brazil: A Scoping Review2
OP72 Clinical And Economic Impact Of The Availability Of Innovative Therapies For Advanced Lung Cancer In Latin America2
PD92 Procedures For Disinvestment Of Health Technologies In Latin America2
PD68 Access To Medications For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: 2012 to 20232
PD119 Interventions To Improve Long COVID Symptoms: A Systematic Review Of Randomized Controlled Trials2
OP13 Improving Case Finding For Celiac Disease In Children And Adults: Evidence Synthesis And Economic Modeling2
PP76 Clinical Guidelines For Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis: Incorporating Rituximab To Enhance Equity In Access And Treatment In Brazil2
OP69 Are Artificial-Intelligence-Based Literature Reviews Accepted By Health Technology Assessment Bodies?2
PP09 Automated Study Selection Flowchart: Direct_Flow2
PP129 Health Technology Assessment Adaptation: Pharyngolaryngeal Biopsies (OLB) For People with Suspected Head and Neck Cancer in the Outpatient Setting2
Ethical challenges for Health Technology Assessment (HTA) in the evolving evidence landscape2
Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia2
PD60 The Importance Of Systematic Reviews Addressing Questions Of Prevalence In Health Technology Assessment2
Expanding access to sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the Ministry of Health Malaysia – a multiple HTA approach2
PP33 Molecular Markers For The Detection Of Clinically Significant Prostate Cancer2
PP51 Critical Analysis Of Budget Impact Analyses For Health Technologies In The Brazilian Supplementary Health System2
PP39 Monitoring Clinical Trial Registers In The Context Of A Systematic Review On Vitamin D For COVID-192
PP53 Potential Cost-Effectiveness And Innovation Headroom Of A More Accurate Companion Diagnostic For PD-L1 In Non-Small-Cell Lung Cancer2
PD25 Identification Of Unmet Medical Needs Through A Health Technology Assessment Process To Guide Research And Development: Experience From A University Hospital2
PD21 Evidence Assessment Frameworks And Economic Modeling For Rare Diseases: A Stakeholder Survey Exploring Current Practices In HTA2
The relative importance of severity and rarity criteria in health resource allocation: an umbrella review2
OD33 Assessment Tool For MHealth Apps To Manage Depression (EvalDepApps Project)2
IOATLAS: scanning across the medical horizon2
PP87 Glecaprevir/pibrentasvir (Maviret®) Remains A Cost-effective Treatment For Chronic Hepatitis C Virus Infection After Changes To The Treated Population2
PP109 Which Review Is Right For You? Choosing A Review Methodology2
PD96 Are Continuous Noninvasive Blood Pressure Monitoring Devices Accurate Enough To Replace Invasive Monitoring? A Rapid Review2
Lifecycle evaluation of medical devices: supporting or jeopardizing patient outcomes? A comparative analysis of evaluation models2
PD07 Cost-Effectiveness Of Direct Oral Anticoagulants In Chinese Patients With Non-Valvular Atrial Fibrillation2
PD57 Drugs For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: Profile Of Budget Impact Analyses2
PP42 Comprehensive Care Program For Polypharmacy Patients: Cafam Experience (Healthcare Provider Institution – Pharmaceutical Manager)2
PP120 Fluorescent In Situ Hybridization (FISH) Vs Conventional Cytogenetic (CC) For Detecting High-Risk Genetic Mutations In Multiple Myeloma2
PD56 Conceptual Issues In The Valuation Of Health States In Children1
PP84 Evaluation Of The Evidence Level Of Scrambler Therapy For Musculoskeletal Pain Relief: A Systematic Literature Review1
PD31 Counting Oncology Patients In The Brazilian Public Health System: A Comprehensive New Methodology1
OP83 Joining Efforts To Improve Patient Involvement In Health Technology Assessment: The Case Of The RedETS Patient Interest Group1
OP88 Translating Patient Reported Measure Score Into Specific Outcomes From The Patient Perspective–Example Using Health Assessment Questionnaire-Disability Index1
OD26 Comparing Health Technology Developers’ Proposed Indication To An Estimated Indication Generated By An International Horizon Scanning Database1
PD39 First Approach For Assessing Statistical Significance In Industry Funded Matching-Adjusted Indirect Comparison Studies: A Scoping Review1
PP100 Improving The Assessment Of Effectiveness For Digital Applications Using The B Statistic: Using WtsWrng As A Case Study1
PP13 Development Of Recommendations And Proposal For A Value-Based Managed Entry Agreement For Italian Setting1
PD116 Development Of A Value Framework For The Appropriate Prescription Of High-Cost Cancer Drugs In A Cancer Center1
PP59 Do Patient Contributions Matter? A Thematic Document Analysis Of NICE Ultra-Rare Disease Appraisals1
OP83 Diagnostic Accuracy And Cost Effectiveness Of Automated Ankle Brachial Pressure Index Measurement For Peripheral Arterial Disease In People With Leg Ulceration1
PP12 Challenges In Assessing The Efficacy Of Non-Pharmacological Measures In The Context Of The COVID-19 Pandemic1
OP51 Targeted Next-Generation Sequencing Gene Panel In Chronic Lymphocytic Leukemia Medical Care1
PD35 A Decade In Review: Assessing The Quality Of Clinical Evidence For Oncology Drugs Submitted To A National Health Technology Assessment Agency1
OP67 Considerations Of Treatment Novelty In Health Technology Assessment1
PP28 Leveraging Social Media For Educating Laypeople On Health Technology Assessment: The Participa SUS/ATS Experience1
Hospital-based health technology assessment of innovative medical devices: insights from a nationwide survey in France1
A systematic literature review of revealed preferences of decision-makers for recommendations of cancer drugs in health technology assessment1
PP24 Creating A Comprehensive Open-Access Health Technology Assessment (HTA) Policy Research Database Through Automated Data Extraction From HTA Reports1
Health technology assessment for oral health in the past decade: a scoping review1
OP51 Improving Childhood Cancer Management And Financing In Ghana: Results From Stakeholder Mapping and Analysis1
OP35 Early Access To Medicinal Products In France: A Positive Evaluation Two Years Into The New Framework1
PP63 Perspectives Of Physical And Organic Disability Organizations On Health Technology Assessment Processes1
OP37 How Can We Make Innovative Payment Schemes Work? Findings Of A European Union Horizon Europe Project1
PP22 A Lifecycle Approach To The Use Of Real-World Evidence In HTA Submissions And Resubmissions: A Decade’s Experience1
Increasing the impact of budget impact analysis: incorporating uncertainty for decision-makers in small markets1
PP30 A Costing Template For The Implementation Of A Public And Patient Advisory Board For Health Research In Dementia1
PD65 Pilot Project Of Horizon Scanning To Inform The Ukrainian Health System About New HIV/AIDS Health Technologies1
OP81 Do Sustainable Healthcare Principles Inform Guidance Development? An Exemplary Case Study In Respiratory Care1
OP168 Costs And Effectiveness Of Whole Exome Sequencing (WES) In Patients With Unsolved Rare Disease Through The Diagnostic Pathway1
Building sustainable health technology assessment capacity in Ukraine1
PP43 Budget Impact Analysis Of Next-Generation Sequencing Coverage In Taiwan’s National Health Insurance1
PP108 Multidimensional Analysis Of Peristeen Plus Medical Device1
OP11 Cost-Effectiveness Of Atezolizumab Plus Chemotherapy As A First-Line Treatment For Metastatic Non-Squamous Non-Small Cell Lung Cancer1
National health technology assessment in Turkiye after a decade: are key principles followed?1
PD185 Is The Incorporation Of Medications For Ultrarare Diseases In Brazil Predominantly Driven By Costs? A Shift In Paradigm1
PD32 Cost-Utility Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Chemotherapy-Refractory Metastatic Colorectal Cancer In Brazil1
PP153 The Economic And Fiscal Impact Of Public Health Programs For Diabetic Patients In Italy1
PD17 Next-Generation Sequencing Gene Panel For Gastrointestinal Stromal Tumor Care1
PD90 Use Of Medicinal Herbs In Natura By Pregnant Women In The Amazon Region1
OP98 Improving Patient Involvement In Health Technology Assessments: Is It Enough To Train Just The Patients?1
OP172 International Collaboration For Translating The Peer Review Of Electronic Search Strategies (PRESS) Checklist: A Harmonized Approach1
PP57 Proposal For Adaptation Of The Pharmaceutical Innovativeness Index Based On Lenacapavir1
Values, principles, strategies, and frameworks underlying patient and public involvement in health technology assessment and guideline development: a scoping review1
European Network for Health Technology Assessment’s Response to COVID-19: Rapid Collaborative Reviews on Diagnostic Tests and Rolling and Rapid Collaborative Reviews on Therapeutics1
PD25 Innovation In Facial Palsy Treatment: The Costs And Benefits Of Telerehabilitation Introduced Into Physical Therapy Pathways1
OP34 Horizon Scanning A Matter Of Collaboration. A Description Of The Processes Of I-HTS Member Organizations1
OP61 Target Trial Emulation To Determine The Population-Level Cost-Effectiveness Of Multigene Panel Sequencing For Advanced Melanoma1
Transferability of a EUnetHTA relative effectiveness assessment to low- and middle-income countries setting1
Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines1
PD18 Cytomegalovirus Prophylaxis With Valganciclovir For HIV-Immunosuppressed Patients: Cost Effectiveness And Budget Impact Analysis From The Brazilian Healthcare System Perspective1
OP35 Suitability Of Preference Methods Across The Medical Product Lifecycle: A Multicriteria Decision Analysis1
OD37 How The PICOTS-ComTeC Framework For Digital Health Interventions Can Be Useful For Health Technology Assessment1
PP82 Environmental Sustainability Assessment Across The Medical Device Life Cycle: Taking The Viewpoint Of Low Resource Settings1
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis1
OP74 Analysis Of Literature And Research Foci In Overdiagnosis Based On Citespace1
Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report1
PP04 Extrapolating Survival Curves In Oncology: Advancing Economic Modeling To Meet Next-Generation Health Technology Assessment Demands1
OD41 Conducting Systematic Reviews On Rare Diseases: Lessons Learned From The European Reference Networks Guidelines Programme1
OP03 The Distribution Of Quality-Adjusted Life Expectancy By Level Of Socioeconomic Disadvantage And Remoteness Area For The Australian Population1
The UK early access to medicines scheme: uptake, approvals, and reimbursement1
PD93 Uncertainty Metric To Guide PICOS Assessment And Evidence Synthesis Planning For Joint Clinical Assessment Submission1
OP54 The Early Detection And Warning System ‘SINTESIS-New Technologies’: A Horizon Scanning Experience In Spain1
OP11 Differences And Similarities In Past Health Technology Assessments In Beneluxa Initiative Countries1
OD17 Future Health And Economic Burden Of Cardiovascular Disease In Type 2 Diabetes In Australia From 2021 To 20311
PD32 Incorporating Environmental Factors Into Health Technology Assessment Submissions: A Scoping Review1
PP14 Value-Based Pricing For Advanced Therapy Medicinal Products: Emerging Affordability Solutions1
OP93 Informing Efficient Diagnostic Monitoring Pathways Using Prospective Cohort Data: A Case Study In Neovascular Age-Related Macular Degeneration1
PP50 Improving The Evaluation Of Devices And Procedures: Impact Of The National Committee For Health Technology Incorporation Subcommittee1
PD173 Semi-Automation Of Systematic Literature Review Title And Abstract Screening Using Text Mining And Classification Techniques1
PP153 Efficacy And Safety of Onasemnogene Abeparvovec For The Treatment Of Patients With Spinal Muscular Atrophy Type 1: Meta-Analysis1
PD51 Strategies For Reducing Cesarean Section Rates: An Overview Of Organizational Interventions1
INAHTA member agency stories of engaging, adaptable, and impactful HTA1
OP45 Incorporation Of The Tetravalent Dengue Vaccine In The Brazilian Public Health System: A Cost–Benefit Analysis1
PP21 Examining Clinical Evidence: Incorporation Of Medications For Ultra-Rare Diseases – Descriptive Analysis Of Conitec Reports (2012 to 2022) – Brazil1
OP43 Incorporating Mathematical Modeling To Improve Accuracy Of Budget Impact Analysis: Using Screening For Hepatitis C As An Example1
OP56 Hospital-Based Health Technology Assessment: Barriers And Facilitators In France, Hungary, Italy, Kazakhstan, Poland, Switzerland, And Ukraine1
Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis1
Priority setting for health technology adoption at the national level: Lessons learned over 25 years’ experience1
PD155 RedETS Horizon Scanning: Impact In The Decision-Making Process1
PP60 Literature Review For Health Technology Assessment (HTA)-Based Decision Making In Brazil: Artificial Urinary Sphincter For Post-Prostatectomy Severe Urinary Incontinence1
OP47 New Health Technology Assessment Framework For Digital Health Technologies1
OP20 Technical Validation Of An Environmental Model: A Multidisciplinary Checklist To Guide Environmental Criteria In Health Technology Assessment1
OP102 Towards Universal Health Coverage: Health Technology Assessment Roadmap Development In The Emirate Of Abu Dhabi Involving The Whole Ecosystem1
Perceptions of patients and caregivers toward the management of rare disease in Malaysia: a qualitative research study0
0.10054278373718